According to a new study published in the peer-reviewed medical journal, The BMJ, the diabetes drugs Januvia, Onglyza and Tradjenta may increase the risk of Inflammatory Bowel Disease. Study participants were monitored for an average of three and a half years. The researchers discovered that use of Januvia, Onglyza and Tradjenta was associated with a 75% increase in the risk of developing Inflammatory Bowel Disease (53.4 cases per 100,000 person years) compared with the use of alternative antidiabetic drugs (34.5 cases per 100,000 person years).
What is Inflammatory Bowel Disease?
Inflammatory Bowel Disease is another term for Crohn’s Disease and Ulcerative Colitis. It is characterized by chronic inflammation of the gastrointestinal tract. Inflammatory Bowel Disease causes severe abdominal discomfort and bloating.
Studies have shown that Inflammatory Bowel Disease along with diabetes can complicate treatment for both. Certain drugs used to treat symptoms Inflammatory Bowel Disease (diarrhea, stomach ache and gastrointestinal inflammation) may raise blood glucose levels. For diabetes patients drugs like metformin can cause side effects like diarrhea, nausea and abdominal pain.
If you or a loved one have taken Januvia, Onglyza or Tradjenta and been diagnosed with Inflammatory Bowel Disease, contact us online or call 1-866-252-3535 for a free consultation.